Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03169244 · ClinicalTrials.gov registry record · Phase 2
Buproprion for Binge Drinking
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT03169244 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 42 participants.
The verdict
NCT03169244, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
The present proposal is an innovative and translational clinical trial derived from exciting preclinical findings to test the hypothesis that treatment with the melanocortin activator bupropion can reduce binge drinking in humans. Furthermore, pilot data on moderating effects of coexisting nicotine use on the efficacy of bupropion for binge drinking population will be obtained. Evidence for an efficacy signal with good tolerability with this FDA approved medication would form the foundation to conduct a well-powered Phase II b trial. The development of an effective pharmacotherapy for binge drinking would be a significant clinical advance. .
Interventions
- DRUG Placebo Oral Tablet
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-09-04 |
| Est. Completion | 2019-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03169244
The ClinicalTrials.gov registry entry for NCT03169244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03169244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03169244 about?
NCT03169244 is a clinical study titled "Buproprion for Binge Drinking". The present proposal is an innovative and translational clinical trial derived from exciting preclinical findings to test the hypothesis that treatment with the melanocortin activator bupropion can reduce binge drinking in humans. Furthermore, pilot data on moderating effects of coexisting nicotine ...
What is the current status of trial NCT03169244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2017-09-04. Estimated completion is 2019-09-17.
What interventions are being tested in trial NCT03169244?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT03169244?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.